Cyclic HPMPC is safe and effective against systemic guinea pig cytomegalovirus infection in immune compromised animals (Q74341366)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10996398%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

title

Cyclic HPMPC is safe and effective against systemic guinea pig cytomegalovirus infection in immune compromised animals (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10996398%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

main subject

cytomegaloviral disease

1 reference

N Bourne

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10996398%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

F J Bravo

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10996398%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

D I Bernstein

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10996398%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

publication date

1 August 2000

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10996398%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10996398%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

volume

47

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10996398%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10996398%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

page(s)

103-109

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10996398%20AND%20SRC:MED&resulttype=core&format=json

Comparative activity of selected antiviral compounds against clinical isolates of human cytomegalovirus

10 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900100-5

7 January 2021

Cytomegalovirus infection in immunocompromised guinea pigs: a model for testing antiviral agents in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900100-5

7 January 2021

Effects of cyclosporine on the pathogenesis of primary cytomegalovirus infection in the guinea pig.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900100-5

7 January 2021

1-[((S)-2-hydroxy-2-oxo-1,4,2-dioxaphosphorinan-5-yl)methyl] cytosine, an intracellular prodrug for (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine with improved therapeutic index in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900100-5

7 January 2021

Effect of passive antibody on congenital cytomegalovirus infection in guinea pigs

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900100-5

7 January 2021

Evaluation of HPMPC therapy for primary and recurrent genital herpes in mice and guinea pigs

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900100-5

7 January 2021

Synthesis and antiviral activity of the nucleotide analogue (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900100-5

7 January 2021

Clinical pharmacokinetics of 1-[((S)-2-hydroxy-2-oxo-1,4,2-dioxaphosphorinan-5-yl)methyl]cytosine in human immunodeficiency virus-infected patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900100-5

7 January 2021

Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine in various models of herpes simplex virus infection in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900100-5

7 January 2021

Antiviral effect of 9-(1,3-dihydroxy-2-propoxymethyl)guanine against cytomegalovirus infection in a guinea pig model

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900100-5

7 January 2021

Peripheral blood mononuclear cell-mediated cytolytic activity during cytomegalovirus (CMV) infection of guinea pigs

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900100-5

7 January 2021

(S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine (cidofovir): results of a phase I/II study of a novel antiviral nucleotide analogue

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900100-5

7 January 2021

Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS. A randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900100-5

7 January 2021

Activity of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) against guinea pig cytomegalovirus infection in cultured cells and in guinea pigs

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900100-5

7 January 2021

Lack of reactivation of cytomegalovirus (CMV) retinitis after stopping CMV maintenance therapy in AIDS patients with sustained elevations in CD4 T cells in response to highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900100-5

7 January 2021

Conversion of 1-[((S)-2-hydroxy-2-oxo-1,4,2-dioxaphosphorinan-5-yl)methyl]cytosine to cidofovir by an intracellular cyclic CMP phosphodiesterase

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900100-5

7 January 2021

Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine for the treatment of murine cytomegalovirus infection in severe combined immunodeficiency mice

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900100-5

7 January 2021

Anticytomegaloviral activity and safety of cidofovir in patients with human immunodeficiency virus infection and cytomegalovirus viruria

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900100-5

7 January 2021

New strategies for prevention and therapy of cytomegalovirus infection and disease in solid-organ transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900100-5

7 January 2021

Cytomegalovirus retinitis in the era of highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900100-5

7 January 2021

10.1016/S0166-3542(00)00100-5

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10996398%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

1 reference